Understanding HFpEF: A New Perspective

Heart failure with preserved ejection fraction, or HFpEF, has long been a source of confusion for medical professionals. Approximately four million Americans, along with over 30 million individuals globally, are affected by this condition, yet effective treatment methods remain sparse.

Unlike traditional heart failure, which involves a weakened heart struggling to pump blood, HFpEF can appear normal in medical imaging. The heart moves blood adequately; however, its inability to relax properly means it can’t fill completely between beats. This rigidity can lead to feelings of breathlessness, fatigue, and occasional swelling in the legs, abdomen, or lungs.

For years, high blood pressure was considered the main villain in this narrative. Recently, though, a new theory suggests otherwise. Milton Packer, a prominent cardiovascular researcher, argues that the heart itself might not be the primary issue.

His research team proposes a notion where signals emanating from fat tissue could be a major contributor to HFpEF. This theory, known as the Adipokine Hypothesis, was shared in a publication and presented at the upcoming European Society of Cardiology Congress.

Fat’s Role Beyond Storage

Many tend to think of fat as merely a storehouse for calories. However, it functions as a dynamic organ that emits chemical signals throughout the body. These signals, called adipokines, are proteins and hormones that can affect heart health, blood vessels, metabolism, and immune responses.

When adipose tissue is healthy, adipokines serve as protectors for organs, diminish inflammation, and assist in regulating fluid levels. Conversely, when fat accumulation becomes excessive and problematic, the nature of these signals alters. Increased levels of harmful adipokines rise, while the beneficial ones diminish.

Packer elaborates that this evolution in fat behavior turns it into a factor that amplifies stress, inflammation, and scarring in the heart. “Until now, we lacked a comprehensive explanation for HFpEF, resulting in significant misunderstandings and an absence of clear diagnostic and treatment paths,” he pointed out. “This innovative framework identifies the underlying cause of HFpEF for many patients, which should significantly improve treatment guidelines.”

How Fat Signals Impact Heart Function

This new perspective outlines various pathways through which unhealthy fat may trigger HFpEF. For instance, inflammation is one aspect. Stressed fat tissue can attract immune cells that release a flood of inflammatory substances.

These substances can harm the lining of blood vessels and heart muscle cells. Another issue is vascular stiffness; when arteries become less pliable, it becomes harder for blood to flow, increasing pressure on the heart. Over time, this can lead to scarring or fibrosis, which further hampers the heart’s ability to relax and fill correctly. And, when metabolic stresses like diabetes or hypertension are in play, everything accelerates further.

The result? A heart that may seem to pump well but fails to supply enough blood to meet the body’s demands during physical activities. Simple tasks, like climbing stairs, can become exhausting—not because the heart can’t contract, but because it can’t fill adequately.

Supporting Evidence for the Adipokine Hypothesis

This hypothesis consolidates findings across various research areas. Patients with HFpEF generally exhibit excess fat stored deep within their bodies, closely associated with their organs, including the heart. Laboratory studies have shown that adipokines can directly impair heart muscle relaxation.

Research on blood vessels has shown that harmful adipokines restrict dilation, contributing to higher blood pressure. Moreover, clinical data indicate that HFpEF frequently occurs in individuals with metabolic syndrome—characterized by obesity, elevated blood sugar, and hypertension—further emphasizing the role of fat.

This theory’s strength lies in its ability to connect various observations under a single framework. Instead of viewing obesity, diabetes, and hypertension as separate issues, it associates them through the biochemical signals issued by fat tissue.

Changing Medical Perspectives

If Packer’s hypothesis holds true, HFpEF isn’t just a heart issue; it’s a disease that affects the entire body, starting with fat. This could change how doctors diagnose and treat the condition. Rather than solely focusing on heart function, they may start looking at markers of inflammation, analyzing fat distribution, and measuring waist-to-height ratios.

Packer emphasizes that traditional measures like body mass index (BMI) might not tell the full story due to their interference from muscle and bone. Instead, waist-to-height ratios could provide better insight. Ideally, this ratio should be below 0.5—meaning your waist should be less than half your height.

Most HFpEF patients exceed this threshold, and many have ratios above 0.6, even if they don’t fit the obesity definition by BMI. “Clinicians should be mindful of HFpEF symptoms in patients with a high waist-to-height ratio,” he noted. Shortness of breath, often attributed to weight issues alone, might point to an underlying treatable heart problem.

Potential Treatments on the Horizon

A compelling implication of this hypothesis is that certain medications might shift fat biology rather than targeting the heart directly. Some drugs, already approved for different applications, appear capable of modifying adipokine profiles. For example, GLP-1 receptor agonists, like semaglutide and tirzepatide, initially developed for diabetes and weight loss, have shown positive effects.

These drugs might help shrink unhealthy fat and normalize signaling pathways, which could lead to reduced inflammation and scarring related to HFpEF. There’s experimental support for this idea, and ongoing clinical trials will shed more light.

Lifestyle changes that help reduce harmful fat—like healthier diets, increased physical activity, or even surgical options—could also prove essential. If validated, this could open a number of new strategies for the millions dealing with the condition.

Looking to the Future

The Adipokine Hypothesis remains a theory, not an established fact. Much of the supporting evidence comes from models and correlations. To further understand which adipokines are most influential, as well as their interactions with other risk factors, more extensive clinical studies are necessary. Still, there’s hope. Packer recalls proposing the neurohormonal hypothesis for a different heart failure type 33 years ago, which ultimately led to transformative treatments. The goal is for this newer hypothesis to inspire a similar shift for HFpEF.

If verified, this hypothesis could reshape both the prevention and treatment landscape for heart failure. Physicians may begin to utilize waist-to-height ratios in screenings, which could facilitate early risk detection. Patients showing higher ratios could be candidates for therapies aimed at reducing harmful fat-related signals.

Already existing medications like semaglutide might find new applications in managing HFpEF. This shift would mean that symptoms like shortness of breath and fatigue, often dismissed as mere weight problems, might actually be treated as serious heart-related issues.

At a public health level, these findings underscore the urgent need to tackle rising obesity rates, especially since HFpEF cases are projected to increase significantly in coming years. By approaching fat as an active organ, ongoing research might uncover new avenues for both prevention and treatment.